44289
GLENMARK PHARMACEUTICALS LIMITED
Mar 30, 2021
India
South Asia
Jul 9, 2020
B - Limited
Completed
Oct 19, 2024
Regional Industry - MAS Asia & Pac
other
Approved : Jul 9, 2020
Signed : Feb 12, 2021
Invested : Apr 15, 2021
other
Glenmark Pharmaceuticals Limited (“Glenmark” or “the Company”) is a global research-led pharmaceutical company with presence across generics, specialty, and OTC business with global presence in over 80 countries. Glenmark’s key therapy focus areas are respiratory, dermatology and oncology. IFC committed an unsecured A loan of US$40 million to Glenmark on February 12, 2021 through an allocation under the IFC COVID-19 response facility to fund the Company's ongoing capital expenditure program in India and proposed refinancing of foreign currency debt maturities (“Project”).
In June 2016, IFC had invested in convertible debt of US$75 million in Glenmark to finance the Company’s expansion project at the time, which has now been completed. The Project (2021 investment) is linked to Glenmark (#38371, 2016 investment): https://disclosures.ifc.org/project-detail/SII/38371/glenmark
For Inquiries About the Project, Contact
For Inquiries and Comments About IFC, Contact